TEVOGEN BIO HOLDINGS INC.

Communiqués Tevogen Bio Holdings Inc.

Actions

TVGN

US88165K1016

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
0,8075 ^USD	+4,33%		-1,52%	-92,74%

13/05	Les investisseurs attendent des données clés sur l'inflation dans les jours à venir, alors que les contrats à terme américains tendent vers une hausse modeste lundi	MT
13/05	Les plus fortes hausses du prémarché	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Tevogen Bio Reports First Quarter 2024 Financial Results	29/05	GL
Tevogen Bio Reports First Quarter 2024 Financial Results	29/05	AQ
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives	16/05	GL
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives	10/05	GL
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives	01/05	GL
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments	26/04	GL
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers	11/04	GL
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development	03/04	GL
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price	28/03	GL
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant	20/03	BU
Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita	05/03	BU
Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI	27/02	BU
Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment	21/02	BU
Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market	17/02	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.

PROFITEZ-EN MAINTENANT